Zyprexa Reduced Hospitalization Rate In CATIE Study Is Key For Payors, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. sales of the antipsychotic fell 10% in the third quarter; CATIE trial results will not boost Zyprexa sales "overnight," COO Lechleiter says.